EFFECTS OF APELIN-12 AND OBESTATIN OF LEFT VENTRICULAR HYPERTROPHY IN PATIENTS WITH ARTERIAL HYPERTENSION DEPENDING ON THE DURATION OF DIABETES MELLITUS TYPE 2

被引:0
|
作者
Kravchun, P. G.
Tabachenko, O. S.
机构
来源
WORLD OF MEDICINE AND BIOLOGY | 2015年 / 50卷 / 02期
关键词
arterial hypertension; diabetes mellitus type 2; left ventricular hypertrophy; apelin-12; obestatin;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
The prevalence of left ventricular hypertrophy associated with arterial hypertension, obesity, diseases of the cardiovascular system, metabolic disorders, diabetes mellitus. The aim of the study was to assess the presence and character of links between apelin-12, obestatin and cardiac hemodynamics parameters for analyzing the effects of these humoral markers on the of left ventricular hypertrophy in patients with arterial hypertension and diabetes mellitus type 2. Severity of left ventricular hypertrophy by parameter left ventricular mass index grew in proportion to the duration of diabetes mellitus type 2 in patients with arterial hypertension. The presence of diabetes mellitus type 2 less than 5 years duration is associated with adaptive apelin-12 and obestatin high activity in patients with arterial hypertension. The presence of the disease with diabetes mellitus type 2 over 5 years in hypertensive patients accompanied by depletion of compensatory reactions of obestatin, and in long-term diabetes mellitus type 2 (over 10 years) - at the expense of obestatin and apelin-12 leads to an increase in the degree of left ventricular hypertrophy in hypertensive patients.
引用
收藏
页码:64 / 68
页数:6
相关论文
共 50 条
  • [31] Glycaemic control and left ventricular hypertrophy in patients with diabetes mellitus
    Rekhraj, S.
    Elder, D. E.
    Nadir, A.
    Noman, A.
    Choy, A. M.
    Lang, C. C.
    EUROPEAN HEART JOURNAL, 2011, 32 : 63 - 63
  • [32] Allopurinol Reduces Left Ventricular Mass in Patients With Type 2 Diabetes and Left Ventricular Hypertrophy
    Szwejkowski, Benjamin R.
    Gandy, Stephen J.
    Rekhraj, Sushma
    Houston, John G.
    Lang, Chim C.
    Morris, Andrew D.
    George, Jacob
    Struthers, Allan D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2013, 62 (24) : 2284 - 2293
  • [33] Dapagliflozin, inflammation and left ventricular remodelling in patients with type 2 diabetes and left ventricular hypertrophy
    Dihoum, Adel
    Brown, Alexander J. M.
    McCrimmon, Rory J.
    Lang, Chim C.
    Mordi, Ify R.
    BMC CARDIOVASCULAR DISORDERS, 2024, 24 (01):
  • [34] ALLOPURINOL REDUCES LEFT VENTRICULAR MASS IN PATIENTS WITH TYPE 2 DIABETES AND LEFT VENTRICULAR HYPERTROPHY
    Szwejkowski, B. R. S.
    Gandy, S. G.
    Rekhraj, S. R.
    Houston, G. H.
    Lang, C. C. L.
    George, J. G.
    Morris, A. D. M.
    Struthers, A. D. S.
    HEART, 2013, 99 : A93 - A93
  • [35] Vascular Disaggregation Effects On Erythrocytes In Patients With Arterial Hypertension With Type 2 Diabetes Mellitus
    Medvedev, I. N.
    RESEARCH JOURNAL OF PHARMACEUTICAL BIOLOGICAL AND CHEMICAL SCIENCES, 2018, 9 (03): : 1193 - 1197
  • [36] Increased prevalence of left ventricular hypertrophy in hypertensive women with type 2 diabetes mellitus
    Alexander Tenenbaum
    Enrique Z Fisman
    Ehud Schwammenthal
    Yehuda Adler
    Michal Benderly
    Michael Motro
    Joseph Shemesh
    Cardiovascular Diabetology, 2
  • [37] Exercise capacity, left ventricular hypertrophy and mortality in individuals with type 2 diabetes mellitus
    Kokkinos, P.
    Faselis, C.
    Nylen, E.
    Manolis, A.
    Pittaras, A.
    Doumas, A.
    Kokkinos, J. P.
    Kyritsi, F.
    Papademetriou, V.
    EUROPEAN HEART JOURNAL, 2010, 31 : 516 - 516
  • [38] Increased prevalence of left ventricular hypertrophy in hypertensive women with type 2 diabetes mellitus
    Tenenbaum, Alexander
    Fisman, Enrique Z.
    Schwammenthal, Ehud
    Adler, Yehuda
    Benderly, Michal
    Motro, Michael
    Shemesh, Joseph
    CARDIOVASCULAR DIABETOLOGY, 2003, 2 (1)
  • [39] 4.25 EKG Left Ventricular Hypertrophy and Risk of Cardiovascular Events in Patients with Type 1 and Type 2 Diabetes Mellitus
    M. Salvetti
    M. L. Muiesan
    B. Stanga
    A. Cimino
    U. Valentini
    A. Paini
    E. Belotti
    L. Micheletti
    C. Aggiusti
    C. Agabiti Rosei
    V. Paderno
    E. Agabiti Rosei
    High Blood Pressure & Cardiovascular Prevention, 2007, 14 (3) : 145 - 145
  • [40] Duration of obesity is not a risk factor for type 2 diabetes mellitus, arterial hypertension and hyperlipidemia
    Hekimsoy, Z
    Oktem, IK
    DIABETES OBESITY & METABOLISM, 2003, 5 (06): : 432 - 437